Incidence of adverse events with telmisartan compared with ACE inhibitors: Evidence from a pooled analysis of clinical trials

Patient Preference and Adherence

Volumn 6, Issue , 2012, Pages 1-9

  Mancia, Giuseppe ^a   Schumacher, Helmut ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Adverse drug event; Angiotensin ii type 1 receptor blockers; Angiotensin converting enzyme inhibitors; Cough; Hypertension

Indexed keywords

ENALAPRIL; LISINOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN;

ADULT; ADVERSE DRUG REACTION; AGE DISTRIBUTION; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ETHNICITY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 84857070833     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S27939     Document Type: Article

References (27)

1. Wassmann S, Nickenig G. The role of the AT1 receptor in the cardiovascular continuum. Eur Heart J. 2004;6 Suppl H:H3-H9.
2. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148:16-29.
3. Yusuf S, Teo KK, Pogue J, et al; on behalf of The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
4. Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens. 2008;26:819-824.
5. Kronish IM, Woodward M, Sergie Z, et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011;123:1611-1621.
6. [No authors listed]. Tolerability and quality of life in ARB-treated patients. Am J Manag Care. 2005;11(13 Suppl):S392-S394.
7. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid? J Hum Hypertens. 1997;11:213-220.
8. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood). 2011;30:91-99.
9. European Medicines Agency. Summary of Product Characteristics. Available at: http://www.emea.europa.eu. Accessed November 3, 2011.
10. Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am J Med. 2010;123:1016-1030.
11. Schumacher H, Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press. 2008;17:32-40.
12. Mancia G, Parodi A, Merlino L, Corrao G. Heterogeneity in antihypertensive treatment discontinuation between drugs belonging to the same class. J Hypertens. 2011;29:1012-1018.
13. Squire B. Angiotensin converting enzyme inhibition in heart failure: clinical trials and clinical practice. Cardiovasc Drugs Ther. 2002;16:67-74.
14. Nunes MI. The relationship between quality of life and adherence to treatment. Curr Hypertens Rep. 2001;3:462-465.
15. Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004;10:499-509.
16. Lee YJ, Tsai JC. Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor-58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus. Metabolism. 2001;50:1346-1350.
17. Morimoto T, Gandhi TK, Fiskio JM, et al. Development and validation of a clinical prediction rule for angiotensin-converting enzyme inhibitor-induced cough. J Gen Intern Med. 2004;19:684-691.
18. Dans AL, Teo K, Gao P, et al. In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events. PLoS One. 2010;5:e13694.
19. Fried TR, Tinetti ME, Towle V, O'Leary JR, Iannone L. Effects of benef its and harms on older persons' willingness to take medication for primary cardiovascular prevention. Arch Intern Med. 2011;171:923-928.
20. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:1598-1605.
21. Dragomir A, Côté R, Roy L, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48:418-425.
22. Ambrosioni E, Borghi C. Pharmacoeconomical and cost-benefit aspects. In: Mancia G, editor. ESH Manual of Hypertension. Amsterdam, The Netherlands: Elsevier; 2008.
23. Williams B, Lacourcière Y, Schumacher H, Gosse P, Neutel JM. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens. 2009;23:610-619.
24. Smith DHG, Neutel JM, Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther. 1998;15:229-240.
25. Neutel JM, Smith DH, Reilly PA. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension. Int J Clin Pract. 1999;53:175-178.
26. Neutel JM, Frishman WH, Oparil S, Papademitriou V, Guthrie G. Comparison of telmisartan with lisinopril in patients with mildto-moderate hypertension. Am J Ther. 1999;6:161-166.
27. Serebruany VL. Realistic assessment of drug-induced adverse events: a double-edged sword. Am J Med. 2010;123:971.